Amylyx Pharmaceuticals Inc
AMLX
查看详细走势图
13.980USD
+0.990+7.62%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.53B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.62%
5天
-2.17%
1月
+16.60%
6月
+78.32%
今年开始到现在
+15.73%
1年
+267.89%
查看详细走势图
TradingKey Amylyx Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Amylyx Pharmaceuticals Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名69/392位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价20.22。中期看，股价处于上升通道。近一个月，市场表现较强，技术面评分较高，但较强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Amylyx Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Amylyx Pharmaceuticals Inc亮点
亮点风险
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
业绩高增长
公司营业收入稳步增长，连续3年增长293.03%
业绩增长期
公司处于发展阶段，最新年度总收入87.37M美元
利润高增长
公司净利润处于行业前列，最新年度总收入87.37M美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值低估
公司最新PE估值-7.80，处于3年历史低位
机构加仓
最新机构持股113.87M股，环比增加1.36%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值773.83K
分析师目标
根据
10
位分析师
强力买入
评级
20.222
目标均价
+45.69%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Amylyx Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Amylyx Pharmaceuticals Inc简介
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
公司代码AMLX
公司Amylyx Pharmaceuticals Inc
CEOKlee (Justin)
网址https://www.amylyx.com/
相关品种
